0001193125-22-077356.txt : 20220415 0001193125-22-077356.hdr.sgml : 20220415 20220316171859 ACCESSION NUMBER: 0001193125-22-077356 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vor Biopharma Inc. CENTRAL INDEX KEY: 0001817229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 430 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-655-6580 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 430 CITY: CAMBRIDGE STATE: MA ZIP: 02142 CORRESP 1 filename1.htm CORRESP

VOR BIOPHARMA INC.

100 Cambridgepark Drive, Suite 101

Cambridge, MA 02140

March 16, 2022

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attn:    Michael Davis
Re:    Vor Biopharma Inc.
   Registration Statement on Form S-3 (File No. 333-263541)
  

Request for Acceleration of Effective Date

 

Acceleration Request

Requested Date:         March 18, 2022

Requested Time:         4:00 p.m. Eastern Time

Mr. Davis:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-263541) (the “Registration Statement”) to become effective on March 18, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Richard Segal of Cooley LLP, counsel to the Registrant, at (617) 937-2332.

[Signature page follows]

Very truly yours,

Vor Biopharma Inc.

By:

  

/s/ Robert Ang

 

Robert Ang

 

Chief Executive Officer and Director

 

cc:

   
   Robert Ang, Vor Biopharma Inc.
Anthony Joyce, Vor Biopharma Inc.
  

Richard Segal, Cooley LLP

Daniel I. Goldberg, Cooley LLP